JP2023511439A5 - - Google Patents
Info
- Publication number
- JP2023511439A5 JP2023511439A5 JP2022544745A JP2022544745A JP2023511439A5 JP 2023511439 A5 JP2023511439 A5 JP 2023511439A5 JP 2022544745 A JP2022544745 A JP 2022544745A JP 2022544745 A JP2022544745 A JP 2022544745A JP 2023511439 A5 JP2023511439 A5 JP 2023511439A5
- Authority
- JP
- Japan
- Prior art keywords
- use according
- protein
- domain
- cancer
- amino acid
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2025247000A JP2026062701A (ja) | 2020-01-28 | 2025-12-12 | がんの治療のためのｉｌ１５／ｉｌ１５ｒアルファヘテロ二量体ｆｃ融合タンパク質 |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202062966976P | 2020-01-28 | 2020-01-28 | |
| US62/966,976 | 2020-01-28 | ||
| PCT/US2021/015552 WO2021155042A1 (en) | 2020-01-28 | 2021-01-28 | Il15/il15r alpha heterodimeric fc-fusion proteins for the treatment of cancer |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2025247000A Division JP2026062701A (ja) | 2020-01-28 | 2025-12-12 | がんの治療のためのｉｌ１５／ｉｌ１５ｒアルファヘテロ二量体ｆｃ融合タンパク質 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2023511439A JP2023511439A (ja) | 2023-03-17 |
| JP2023511439A5 true JP2023511439A5 (enExample) | 2024-02-05 |
Family
ID=74672461
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022544745A Withdrawn JP2023511439A (ja) | 2020-01-28 | 2021-01-28 | がんの治療のためのｉｌ１５／ｉｌ１５ｒアルファヘテロ二量体ｆｃ融合タンパク質 |
| JP2025247000A Pending JP2026062701A (ja) | 2020-01-28 | 2025-12-12 | がんの治療のためのｉｌ１５／ｉｌ１５ｒアルファヘテロ二量体ｆｃ融合タンパク質 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2025247000A Pending JP2026062701A (ja) | 2020-01-28 | 2025-12-12 | がんの治療のためのｉｌ１５／ｉｌ１５ｒアルファヘテロ二量体ｆｃ融合タンパク質 |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US20230149509A1 (enExample) |
| EP (1) | EP4096698A1 (enExample) |
| JP (2) | JP2023511439A (enExample) |
| KR (1) | KR20220132598A (enExample) |
| CN (1) | CN115397456A (enExample) |
| AU (1) | AU2021213767A1 (enExample) |
| BR (1) | BR112022014849A2 (enExample) |
| CA (1) | CA3165460A1 (enExample) |
| IL (1) | IL294944A (enExample) |
| MX (1) | MX2022009100A (enExample) |
| TW (1) | TW202136318A (enExample) |
| WO (1) | WO2021155042A1 (enExample) |
Families Citing this family (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| BR112019007281A2 (pt) * | 2016-10-14 | 2019-07-09 | Xencor Inc | proteína heterodimérica, composições de ácido nucleico e de vetor de expressão, vetor de expressão, célula hospedeira, e, métodos para produzir proteína heterodimérica e para tratar câncer em um paciente |
| AU2018291497A1 (en) | 2017-06-30 | 2020-01-16 | Xencor, Inc. | Targeted heterodimeric Fc fusion proteins containing IL-15/IL-15Ra and antigen binding domains |
| JP7516254B2 (ja) | 2018-04-18 | 2024-07-16 | ゼンコア インコーポレイテッド | Ｉｌ－１５／ｉｌ－１５ｒａヘテロ二量体ｆｃ融合タンパク質およびその使用 |
| KR20210003813A (ko) | 2018-04-18 | 2021-01-12 | 젠코어 인코포레이티드 | IL-15/IL-15Rα Fc-융합 단백질 및 LAG-3 항원 결합 도메인을 함유하는 LAG-3 표적화 이종이량체 융합 단백질 |
| CN113438961A (zh) | 2018-12-20 | 2021-09-24 | Xencor股份有限公司 | 含有IL-15/IL-15Rα和NKG2D抗原结合结构域的靶向异二聚体Fc融合蛋白 |
| TW202128757A (zh) | 2019-10-11 | 2021-08-01 | 美商建南德克公司 | 具有改善之特性的 PD-1 標靶 IL-15/IL-15Rα FC 融合蛋白 |
| IL310372A (en) * | 2021-07-28 | 2024-03-01 | Genentech Inc | Il15/il15r alpha heterodimeric fc-fusion proteins for the treatment of blood cancers |
| EP4380596A1 (en) * | 2021-08-04 | 2024-06-12 | Genentech, Inc. | Il15/il15r alpha heterodimeric fc-fusion proteins for the expansion of nk cells in the treatment of solid tumours |
| WO2024011179A1 (en) | 2022-07-07 | 2024-01-11 | Genentech, Inc. | Combinations of il15/il15r alpha heterodimeric fc-fusion proteins and fcrh5xcd3 bispecific antibodies for the treatment of blood cancers |
| KR20250058784A (ko) * | 2022-08-05 | 2025-04-30 | 스테이드슨 바이오팔마 아이엔씨. | 마스킹 폴리펩티드, 활성화 가능한 신규의 프로드럭 및 이의 사용 방법 |
| WO2025085781A1 (en) | 2023-10-19 | 2025-04-24 | Genentech, Inc. | Combinations of il15/il15r alpha heterodimeric fc-fusion proteins and her2xcd3 bispecific antibodies for the treatment of her2-positive cancers |
| WO2025233861A1 (en) * | 2024-05-08 | 2025-11-13 | Suzhou Forlong Biotechnology Co., Ltd. | Long-acting il-15 agonist for treating tumor |
| WO2025252840A1 (en) | 2024-06-04 | 2025-12-11 | Technische Universitaet Muenchen, In Vertretung Des Freistaates Bayern | Half-life modulation by a tag comprising at least one constant domain of an immunoglobulin light chain |
Family Cites Families (39)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6551576B1 (en) | 1989-12-22 | 2003-04-22 | Bristol-Myers Squibb Medical Imaging, Inc. | Container with multi-phase composition for use in diagnostic and therapeutic applications |
| ES2027518A6 (es) | 1990-12-18 | 1992-06-01 | Andromaco Lab | Procedimiento para la preparacion de nuevas asociaciones no covalentes polisacarido-proteina con actividad farmacologica. |
| US7083572B2 (en) | 1993-11-30 | 2006-08-01 | Bristol-Myers Squibb Medical Imaging, Inc. | Therapeutic delivery systems |
| US5874105A (en) | 1996-01-31 | 1999-02-23 | Collaborative Laboratories, Inc. | Lipid vesicles formed with alkylammonium fatty acid salts |
| US6071535A (en) | 1996-01-31 | 2000-06-06 | Collaborative Laboratories, Inc. | Lipid vesicles formed with alkylammonium fatty acid salts |
| US6120751A (en) | 1997-03-21 | 2000-09-19 | Imarx Pharmaceutical Corp. | Charged lipids and uses for the same |
| WO1998048032A2 (en) | 1997-04-21 | 1998-10-29 | Donlar Corporation | POLY-(α-L-ASPARTIC ACID), POLY-(α-L-GLUTAMIC ACID) AND COPOLYMERS OF L-ASP AND L-GLU, METHOD FOR THEIR PRODUCTION AND THEIR USE |
| US7195780B2 (en) | 2002-10-21 | 2007-03-27 | University Of Florida | Nanoparticle delivery system |
| US7449443B2 (en) | 2000-03-23 | 2008-11-11 | California Institute Of Technology | Method for stabilization of proteins using non-natural amino acids |
| US6586207B2 (en) | 2000-05-26 | 2003-07-01 | California Institute Of Technology | Overexpression of aminoacyl-tRNA synthetases for efficient production of engineered proteins containing amino acid analogues |
| US6824790B2 (en) | 2002-01-09 | 2004-11-30 | Enzrel Inc. | Liposome drug delivery of polycyclic, aromatic, antioxidant or anti-inflammatory compounds |
| WO2003066859A2 (en) | 2002-02-07 | 2003-08-14 | Yissum Research Development Company Of The Hebrew University Of Jerusalem | Amino acid sequences capable of facilitating penetration across a biological barrier |
| WO2003073238A2 (en) | 2002-02-27 | 2003-09-04 | California Institute Of Technology | Computational method for designing enzymes for incorporation of amino acid analogs into proteins |
| US7090868B2 (en) | 2002-09-13 | 2006-08-15 | University Of Florida | Materials and methods for drug delivery and uptake |
| WO2004056875A1 (en) | 2002-12-23 | 2004-07-08 | Wyeth | Antibodies against pd-1 and uses therefor |
| US8088734B2 (en) | 2003-01-21 | 2012-01-03 | Unigene Laboratories Inc. | Oral delivery of peptides |
| WO2005094785A2 (en) | 2003-09-17 | 2005-10-13 | Chiasma, Ltd. | Compositions capable of facilitating penetration across a biological barrier |
| SG176455A1 (en) | 2003-10-09 | 2011-12-29 | Ambrx Inc | Polymer derivatives |
| CN103755800B (zh) | 2004-02-02 | 2016-02-24 | Ambrx公司 | 经修饰的人类生长激素多肽与其用途 |
| WO2006097793A2 (en) | 2004-04-15 | 2006-09-21 | Chiasma, Ltd. | Compositions capable of facilitating penetration across a biological barrier |
| WO2006062506A1 (en) | 2004-12-03 | 2006-06-15 | Enzrel, Inc. | Chitosan-coated liposome drug delivery of antioxidant or anti-inflammatory compounds |
| PL2161336T5 (pl) | 2005-05-09 | 2017-10-31 | Ono Pharmaceutical Co | Ludzkie przeciwciała monoklonalne przeciwko białku Programmed Death 1 (PD-1) oraz sposoby leczenia raka z zastosowaniem samych przeciwciał anty-PD-1 lub w połączeniu z innymi środkami immunoterapeutycznymi |
| CA2612241C (en) | 2005-07-01 | 2018-11-06 | Medarex, Inc. | Human monoclonal antibodies to programmed death ligand 1 (pd-l1) |
| US20070184076A1 (en) | 2006-02-07 | 2007-08-09 | Unger Evan C | Liquid-filled nanodroplets for anti-cancer therapy |
| IL188647A0 (en) | 2008-01-08 | 2008-11-03 | Orina Gribova | Adaptable structured drug and supplements administration system (for oral and/or transdermal applications) |
| RU2531758C2 (ru) | 2008-02-11 | 2014-10-27 | Куретек Лтд. | Моноклональные антитела для лечения опухолей |
| US8168757B2 (en) | 2008-03-12 | 2012-05-01 | Merck Sharp & Dohme Corp. | PD-1 binding proteins |
| KR101001360B1 (ko) | 2008-06-16 | 2010-12-14 | (주)기가레인 | 전자 기기의 접지에 전기적으로 연결되는 인쇄회로기판 |
| JP2012500652A (ja) | 2008-08-25 | 2012-01-12 | アンプリミューン、インコーポレーテッド | 標的化共刺激ポリペプチドおよび癌を処置するための使用方法 |
| ES2545609T3 (es) | 2008-08-25 | 2015-09-14 | Amplimmune, Inc. | Composiciones de antagonistas de PD-1 y métodos de uso |
| EP3192811A1 (en) | 2009-02-09 | 2017-07-19 | Université d'Aix-Marseille | Pd-1 antibodies and pd-l1 antibodies and uses thereof |
| US20130017199A1 (en) | 2009-11-24 | 2013-01-17 | AMPLIMMUNE ,Inc. a corporation | Simultaneous inhibition of pd-l1/pd-l2 |
| SI2699264T1 (en) | 2011-04-20 | 2018-08-31 | Medimmune Llc | Antibodies and other molecules that bind b7-h1 and pd-1 |
| RU2604814C2 (ru) | 2011-07-24 | 2016-12-10 | Кьюртек Лтд. | Варианты гуманизированных иммуномодулирующих моноклональных антител |
| ES2774962T3 (es) | 2013-03-05 | 2020-07-23 | Enteris Biopharma Inc | Productos farmacéuticos de administración oral |
| US10259887B2 (en) | 2014-11-26 | 2019-04-16 | Xencor, Inc. | Heterodimeric antibodies that bind CD3 and tumor antigens |
| JP6910950B2 (ja) | 2015-01-12 | 2021-07-28 | エンテリス・バイオファーマ・インコーポレイテッドＥｎｔｅｒｉｓ Ｂｉｏｐｈａｒｍａ，Ｉｎｃ． | 固形経口剤形 |
| BR112019007281A2 (pt) * | 2016-10-14 | 2019-07-09 | Xencor Inc | proteína heterodimérica, composições de ácido nucleico e de vetor de expressão, vetor de expressão, célula hospedeira, e, métodos para produzir proteína heterodimérica e para tratar câncer em um paciente |
| JP7516254B2 (ja) * | 2018-04-18 | 2024-07-16 | ゼンコア インコーポレイテッド | Ｉｌ－１５／ｉｌ－１５ｒａヘテロ二量体ｆｃ融合タンパク質およびその使用 |
-
2021
- 2021-01-28 JP JP2022544745A patent/JP2023511439A/ja not_active Withdrawn
- 2021-01-28 KR KR1020227029305A patent/KR20220132598A/ko active Pending
- 2021-01-28 MX MX2022009100A patent/MX2022009100A/es unknown
- 2021-01-28 WO PCT/US2021/015552 patent/WO2021155042A1/en not_active Ceased
- 2021-01-28 EP EP21707111.7A patent/EP4096698A1/en active Pending
- 2021-01-28 BR BR112022014849A patent/BR112022014849A2/pt unknown
- 2021-01-28 AU AU2021213767A patent/AU2021213767A1/en active Pending
- 2021-01-28 CA CA3165460A patent/CA3165460A1/en active Pending
- 2021-01-28 IL IL294944A patent/IL294944A/en unknown
- 2021-01-28 CN CN202180010911.0A patent/CN115397456A/zh active Pending
- 2021-01-28 TW TW110103329A patent/TW202136318A/zh unknown
-
2022
- 2022-07-22 US US17/814,456 patent/US20230149509A1/en active Pending
-
2025
- 2025-12-12 JP JP2025247000A patent/JP2026062701A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2018070648A5 (enExample) | ||
| JP2020500016A5 (enExample) | ||
| JP2021515559A5 (enExample) | ||
| JP2009505676A5 (enExample) | ||
| RU2019134352A (ru) | Новые биспецифические антигенсвязывающие молекулы, обладающие способностью специфически связываться с cd40 и fap | |
| JP2018523686A5 (enExample) | ||
| de Miguel et al. | T-cell–engaging Therapy for Solid Tumors | |
| JP2018529312A5 (enExample) | ||
| RU2014111999A (ru) | Антитела к C10RF32 и их применения для лечения рака | |
| RU2013142004A (ru) | Конъюгаты "антитело-лекарственное средство" | |
| JP2008531576A5 (enExample) | ||
| Liu et al. | Enhancing tumor immunotherapy by multivalent anti‐PD‐L1 nanobody assembled via ferritin nanocage | |
| Mendelsohn | Antibody-mediated EGF receptor blockade as an anticancer therapy: from the laboratory to the clinic | |
| JP2021511013A (ja) | シングルドメイン抗体−シトシンデアミナーゼ融合タンパク質 | |
| JP2021511372A5 (enExample) | ||
| TW201536319A (zh) | 抗腫瘤劑及抗腫瘤效果增強劑 | |
| TW201726172A (zh) | 含有免疫調節劑之抗腫瘤劑及抗腫瘤效果增強劑 | |
| Bu et al. | Phase I clinical trial of autologous CLL1 CAR-T therapy for pediatric patients with relapsed and refractory acute myeloid leukemia | |
| CN113943371A (zh) | 一种抗her2/抗pd-l1双功能抗体及其应用 | |
| Yang et al. | Peptide vaccine against glioblastoma: from bench to bedside | |
| Shinde et al. | Polyspecificity-an emerging trend in the development of clinical antibodies | |
| CN114585391A (zh) | 西妥昔单抗-ir700偶联物组合物 | |
| CN109663130B (zh) | Pd-1抗体和mek抑制剂联合在制备治疗肿瘤的药物中的用途 | |
| Rumfiled et al. | Combination therapies for HPV-associated malignancies | |
| Wang et al. | Trial-in-progress: a phase 1/2 multi-center study of Onct-808, a ROR1-specific CAR T, in adult patients with relapsed/refractory aggressive B cell lymphoma |